10 YEARS BIOHELLENIKA
10 YEARS BIOHELLENIKA
10 years innovation, research and development, quality, security and investment in Biotechnology
Biohellenika was established on 03/08/2006 by academic doctors, qualified in clinical and laboratory medicine in order to create an international Biotechnology Company. We invest in quality and innovation and besides the circumstances in Greece we keep our ethics and move on in to the field of sciences that we know very well. Biohellenika has owned two labs in Greece, one in Thessaloniki that covers an area of 2500 sq m and a second in Athens that covers 800 sq m.
Biohellenika today offers services related to stem cells as:
1. Therapeutic Department and a team of doctors ready to study each case, to decide and finally to apply stem cells for treatment. 876 patients were treated for cerebral palsy, autism, heart failure, chronic obstructive pulmonary disease, idiopathic lung fibrosis, burns, diabetic foot, woods, osteoarthritis and cartilage degeneration.
2. International Accreditation by AABB (American Association of Blood Banks) that enables all cells that are stored in Biohellenika to use all over the world.
3. International traceability system that guards the storage facilities.
4. National Accreditation system for the quality controls. No one of the quality tests is excluded from this accreditation.
5. We apply the PCR method (DNA) for virology tests. With this tests the final decision for permanent storage is ready in 10 days after delivery, otherways in the case of antibody tests, all tests must be repeated in six months and then the cells are ready to cryopreserved permanently.
6. Its presence in seven countries
7. New products are applied to Orthopedics, Ophthalmologists, Dermatologists, Neurologists, Pulmonologists, and Plastic Surgeons.
8. Five patents Granted
9. 24 published papers from five clinical trials and research projects
10. Five PhD thesis are supported
11. Five financed projects are completed
12. Characterized by the General Secretary for Research and Technology as high class innovative company.
13. Six awards
Biohellenika offers hematopoietic stem cells from cord puncture, placenta drainage and mesenchymal stem cells from umbilical cord tissue. Placenta drainage and cord tissue are protected by patents. Cord puncture and placenta drainage offers the total number of hematopoietic stem cells that are used in malignant diseases treatment, in autologous or allogeneic application, according to histocompatibility and the weight of the patient. It is important to collected the biggest amount of stem cells with both ways. The results of this method was published in Transfusion 2011. v 51, p: 976.
Biohellenika offers ready to use mesenchymal stem cells from the total length of cord by enzymatic digestion. Never preserves the cord in pieces, because it is well known from the literature and from our experience that freezing the tissue all included mesenchymal cells are damaged after thawing. The results of this methods are published in Transfusion Medicine 2011 Aug;21(4):253-61
CORD BLOOD STEM CELLS FOR CEREBRAL PALSY TREATMENT
During the last years in many countries cord blood is used to improve the cerebral palsy clinical condition. Recently Melbourne University Hospital announced the use of autologous cord blood in children with cerebral palsy until the age of 10 years. 16 children are treated in Biohellenika with own stem cells, two of them participates in the clinical trial of Duke University. Results of this application is published in Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy.
Cotton M et al 2014. Journal of Pediatrics, 164(5):973-979
CORD BLOOD STEM CELLS AND MESENCHYMAL STEM CELLS IN AUTISM TREATMENT
Autism became very common between children during last years and 1/8 children in USA are diagnosed with behaviour difficulties. The cause of autism is autoimmunity and gene mutations. Usually children with mutations or chromosome abnormalities have more serious problems in personal performance than those with autoimmunity and stem cells are not used in these cases. On the autoimmunity base both types of cells have good effect. In Biohellenika 290 children with no genes mutations are treated with hematopoietic and mesenchymal cells. The combination of two types gives better results. Children with no stem cells from birth underwent liposuction and mesenchymal stem cells are collected from adipose tissue. Results from autism treatment is published in:
1. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. Lv YT at al, J Transl Med. 2013 Aug 27;11:196.
2. Transplantation of umbilical cord blood mononuclear cells increases levels of nerve growth factor in the cerebrospinal fluid of patients with autism. Li Q, et al, Genet Mol Res. 2015 Jul 31;14(3):8725-32.
Biohellenika provides its accredited laboratories to a licensed by FDA clinical trial published in ClinicalTrials.gov NCT02449005.
Biohellenika offers its accredited labs to a group of dentists of Thessaloniki Dental School to develop and to evaluate a protocol to treat periodontal disease with stem cells from upper jaw bone marrow.
Also Biohellenika provides stem cells from milk and winsdom tooth and for children who had stored pulp tissue stem cells it would not be necessary to aspirate bone marrow in an adult age. Young stem cells are more effective than adult.
In this trial 17 patients will participate and is expected to finished in 2017. Preliminary results are very encouraging.
Dr Kouzi-Koliakou MD, PhD
Medical Director of Biohellenika
Professor of Medicine